885685-56-3

Basic information

• Product Name: lithium 4-{[20(tritylthio)ethyl]amino}pyrimidine-5-carboxylate
• Synonyms: lithium 4-{[20(tritylthio)ethyl]amino}pyrimidine-5-carboxylate
• CAS NO: 885685-56-3
• Molecular Weight: 447.487
• Mol File: 885685-56-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: lithium 4-{[20(tritylthio)ethyl]amino}pyrimidine-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: lithium 4-{[20(tritylthio)ethyl]amino}pyrimidine-5-carboxylate(885685-56-3)
• EPA Substance Registry System: lithium 4-{[20(tritylthio)ethyl]amino}pyrimidine-5-carboxylate(885685-56-3)

Safety Data

• Hazardous Substances Data: 885685-56-3(Hazardous Substances Data)

Upstream product

• 4786-52-1 ethyl 4-hydroxypyrimidine-5-carboxylate 
• 76-83-5 trityl chloride 
• 1095-85-8 2-amino tritylthio ethane 
• 41103-17-7 ethyl 4-chloropyrimidine-5-carboxylate 

Relevant articles and documents

PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP) RECEPTOR (VPAC2) AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE

This invention provides peptides with novel modifications that provide suitable derivatization sites to improve the pharmacokinetic properties of the peptides. These modified peptides function in vivo as agonists of the VPAC2 receptor. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, for example, type 2 diabetics.

GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE

This invention provides peptides with novel modifications that provide suitable derivatization sites to improve the pharmacokinetic properties of the peptides. These modified peptides function in vivo as agonists of the GIP receptor. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, for example, type 2 diabetics.

SELECTIVE NEUROPEPTIDE Y2 RECEPTOR AGONISTS

This invention provides peptides that act as selective NPY2 receptor agonists and may be used to reduce food intake. The invention includes a peptide selected from a specific group of derivatized NPY-related peptides, or functional equivalents thereof. The invention is also directed to a method of treating obesity or related diseases in a mammal comprising administering a therapeutically effective amount of the peptide to said mammal to reduce food intake and body weight.